Skip to content
Home / Companies / GILD GIL
GILEAD SCIENCES, INC. (GILD) S&P 500 NASDAQ-100 XNAS BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Net insider selling (90d)
Latest GILD Insider Trades
About GILEAD SCIENCES, INC. (GILD) Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Headquarters FOSTER CITY, CA
Employees 17,000
Listed 1992
Exchange XNAS https://www.gilead.com SEC filings for GILD on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 26 111,000 $15.02M Option exercise 27 138,990 Tax withholding / forfeiture 6 10,349
GILD Insider Transactions (Form 4) 87 102 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 3.
Date Insider Transaction Security Shares Price Value Aug 26, 2026 AW Anthony Welters - Director Option exercise Common Stock 7,718
Recent GILD Form 8-K Filings 5
Recent GILD Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 26, 2026 ANTHONY WELTERS Director 18,000 $2.68M View on EDGAR Aug 20, 2026 JEFFREY BLUESTONE Director
GILD Insider Trading - FAQ
What is the latest insider trade for GILD? GILEAD SCIENCES, INC. (GILD) had 17 insider filings in the last 90 days, with the most recent on 2026-08-27. The full record for GILD runs to 102 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying GILD stock? No insider purchases of GILD were filed in the last 90 days.
How many insiders are selling GILD stock? 26 insider sales of GILD were filed in the last 90 days, totaling $15.02M.
Where can I see GILD SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks GILD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow GILD insider buys? Create a free InsiderAlpha account and press Watch on this page to add GILD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track GILD insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free $685K
Market cap $180.64B
P/E ratio -
Dividend yield 2.27%
Average volume 7.57M
52 week high $157.29
52 week low $108.46
Today's high $149.47
Today's low $144.88
Open $149.47
Volume 3.95M
Previous close $148.86
Shares outstanding 1.24B Market cap
$180.64B
17,000 employees
GILD Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 26 sales totaling $15.02M.
Most-Active GILD Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 26, 2026 AW Anthony Welters - Director Open-market sale Common Stock 3,118 $148.31 $462K
Aug 26, 2026 AW Anthony Welters - Director Open-market sale Common Stock 4,600 $148.82 $685K
Aug 26, 2026 AW Anthony Welters - Director Option exercise Common Stock 10,282 $61.35 $631K
Aug 26, 2026 AW Anthony Welters - Director Open-market sale Common Stock 3,402 $148.24 $504K
Aug 26, 2026 AW Anthony Welters - Director Open-market sale Common Stock 6,880 $148.82 $1.02M
Aug 26, 2026 AW Anthony Welters - Director Option exercise Non-qualified Stock Option (Right to Buy) 7,718 $0.00 -
Aug 26, 2026 AW Anthony Welters - Director Option exercise Non-qualified Stock Option (Right to Buy) 10,282 $0.00 -
Aug 20, 2026 JB Jeffrey Bluestone - Director Open-market sale Common Stock 1,165 $143.75 $167K
Aug 20, 2026 JB Jeffrey Bluestone - Director Option exercise Common Stock 1,816 $67.45 $122K
Aug 20, 2026 JB Jeffrey Bluestone - Director Open-market sale Common Stock 1,816 $144.92 $263K
Aug 20, 2026 JB Jeffrey Bluestone - Director Option exercise Common Stock 1,658 $67.45 $112K
Aug 20, 2026 JB Jeffrey Bluestone - Director Open-market sale Common Stock 1,658 $145.73 $242K
Aug 20, 2026 JB Jeffrey Bluestone - Director Option exercise Non-qualified Stock Option (Right to Buy) 4,665 $0.00 -
Aug 20, 2026 JB Jeffrey Bluestone - Director Option exercise Non-qualified Stock Option (Right to Buy) 335 $0.00 -
Aug 17, 2026 JM Johanna Mercier - Officer Option exercise Common Stock 1,890 $72.34 $137K
Aug 17, 2026 JM Johanna Mercier - Officer Option exercise Common Stock 23,110 $66.64 $1.54M
Aug 17, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 16,530 $137.37 $2.27M
Aug 17, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 11,470 $138.04 $1.58M
Aug 17, 2026 JM Johanna Mercier - Officer Option exercise Non-qualified Stock Option (Right to Buy) 23,110 $0.00 -
Aug 17, 2026 JM Johanna Mercier - Officer Option exercise Non-qualified Stock Option (Right to Buy) 1,890 $0.00 -
Jul 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 3,000 $129.92 $390K
Jun 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 1,480 $123.42 $183K
Jun 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 1,070 $124.00 $133K
Jun 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 450 $125.40 $56K
Jun 10, 2026 DB Dietmar Berger - Officer Tax withholding / forfeiture Common Stock 263 $121.48 $32K
Jun 10, 2026 DB Dietmar Berger - Officer Option exercise Common Stock 533 - -
Jun 10, 2026 DB Dietmar Berger - Officer Option exercise Restricted Stock Unit 533 - -
Jun 10, 2026 AD Andrew D. Dickinson - Officer Tax withholding / forfeiture Common Stock 1,341 $121.48 $163K
Jun 10, 2026 JM Johanna Mercier - Officer Option exercise Restricted Stock Unit 2,796 - -
Jun 10, 2026 JM Johanna Mercier - Officer Tax withholding / forfeiture Common Stock 1,341 $121.48 $163K
Jun 10, 2026 DO Daniel Patrick O'Day - Officer Tax withholding / forfeiture Common Stock 4,213 $121.48 $512K
May 15, 2026 JM Johanna Mercier - Officer Option exercise Common Stock 25,000 $66.64 $1.67M
May 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 7,749 $130.29 $1.01M
May 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 11,177 $131.19 $1.47M
May 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 8,374 $132.23 $1.11M
May 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 700 $132.75 $93K
May 15, 2026 JM Johanna Mercier - Officer Option exercise Non-qualified Stock Option (Right to Buy) 25,000 $0.00 -
Apr 30, 2026 JB Jeffrey Bluestone - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 30, 2026 JB Jacqueline K. Barton - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 30, 2026 SH Sandra Horning - Director Grant or award Common Stock 1,146 $0.00 -
Apr 30, 2026 SH Sandra Horning - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 30, 2026 TL Ted W. Love - Director Grant or award Common Stock 1,146 $0.00 -
Apr 30, 2026 TL Ted W. Love - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 30, 2026 JR Javier Rodriguez - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 30, 2026 AW Anthony Welters - Director Grant or award Common Stock 1,146 $0.00 -
Apr 30, 2026 AW Anthony Welters - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 30, 2026 HM Harish Manwani - Director Tax withholding / forfeiture Common Stock 224 $130.84 $29K
Apr 30, 2026 HM Harish Manwani - Director Grant or award Common Stock 1,146 $0.00 -
Apr 30, 2026 HM Harish Manwani - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 30, 2026 KK Kelly A. Kramer - Director Grant or award Restricted Stock Unit 1,146 $0.00 -
Apr 30, 2026 KK Kelly A. Kramer - Director Grant or award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 -
Apr 15, 2026 JM Johanna Mercier - Officer Open-market sale Common Stock 3,000 $140.96 $423K
$GPCR
Structure Therapeutics Inc.
